Psyence Group Completes Export of Psilocybin Mushrooms to Canada Post published:September 22, 2022 Post category:Press Release
Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) Post published:September 19, 2022 Post category:Press Release
Psyence Group Announces Amendment and Closing of Previously Announced Private Placement Post published:September 8, 2022 Post category:Press Release
Filament Health and Psyence Enter into Exclusive Licensing Agreement for Natural Psilocybin Products Post published:April 19, 2022 Post category:Press Release
Psyence Group Announces DTC Eligibility Approval in the U.S. Post published:February 9, 2022 Post category:Press Release
Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility Post published:February 7, 2022 Post category:Press Release
Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts Post published:September 28, 2021 Post category:Press Release
Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial Post published:July 7, 2021 Post category:Press Release
Psyence Group Announces Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development Post published:June 17, 2021 Post category:Press Release